10:57 AM EDT, 07/10/2026 (MT Newswires) -- Sanofi (SAN.PA) said Friday the US Food and Drug Administration approved the subcutaneous formulation of Sarclisa Escena for the treatment of multiple myeloma across all existing indications of the drug's intravenous formulation. The approval follows several trials, including the Iraklia phase 3 noninferiority study, which showed that the subcutaneous version of the French pharmaceutical group's treatment worked as well as intravenous infusion. Sanofi added that Sarclisa Escena, combined with standard-of-care regimens, becomes the first anticancer therapy in the US to be administered through both an on-body injector and manual subcutaneous administration.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.